| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
DES PLAINES, Ill.—Abbott reports that it will expand its existing agreement withGlaxoSmithKline (GSK) to include the development of anadditional companion diagnostic test in support of GSK's cancerimmunotherapy research program. 
 
The existing agreements between Abbott and GlaxoSmithKline Biologicals S.A., announced in July2009 and March 2010, focused on the development of  polymerase chainreaction (PCR) tests to screen non-small cell lung cancer and melanomatumors for expression of the MAGE-A3 antigen. Under the expandedagreement, Abbott will develop a PCR test for use on the Abbott m2000rt instrumentto screen non-small cell lung cancer tumors for the expression of thePRAME antigen. PRAME is a preferentially expressed antigen of melanomathat is expressed in 69 percent of non-small cell lung cancer cases, aswell as in a wide variety of cancer types, including melanoma, breast,ovarian, and bladder cancer, with limited expression in normal cells.
 
Abbott's sees its development efforts in areas such as MAGE-A3 and PRAME as being among they keys to further building its leadership position in cancer diagnostics andpersonalized medicine.
 
"This expanded collaboration, along with Abbott's other recentlyannounced partnerships in oncology, demonstrates the continuedcommitment Abbott is making to assess biomarkers linked toimmunotherapies in various cancers," said Stafford O'Kelly, head ofAbbott's molecular diagnostics business. "This agreement is a testamentto the scientific advances Abbott and the industry is making inpersonalized medicine and companion diagnostics, which are helpingensure the right medicines get to the right cancer patients."

GSK's antigen-specific cancer immunotherapy (ASCI) program is focused on a novel class of medicines designed to trainthe immune system to recognize and eliminate cancer cells in a highlyspecific manner. These novel cancer immunotherapeutics combine tumorantigens, delivered as purified recombinant proteins, and GSK'sproprietary Adjuvant Systems, which are specific combinations ofimmunostimulating compounds selected to increase the anti-tumor immuneresponse.
 
As GSK and Abbott note, ASCIs are being investigated in the clinic to support theiruse to reduce the risk of tumor recurrence following surgery, or toimpact tumor growth in an early metastatic setting. The highly specificmode of action of GSK's ASCIs is said to allow development of diagnostic tools toaid in selecting patients eligible for the treatment, depending on theexpression of the tumor antigens.
 
MAGE-A3 is a tumor-specific antigen that is expressed in a largevariety of cancers, including melanoma, non-small cell lung, head andneck, and bladder cancer, with no expression in normal cells. Expressionof the MAGE-A3 gene has been observed in testicular cells but withoutantigen presentation capabilities. MAGE-A3 protein has been in-licensedby GSK from the Ludwig Institute for Cancer Research, reportedly the largestinternational academic institute dedicated to understanding andcontrolling cancer.
 
SOURCE: GSK/Abbott news release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue